Login | Register

Postherpetic Neuralgia – GlaxoSmithKline And XenoPort Receive FDA Approval For Horizant

FDA approval is always welcome news, especially to patients needing treatment and stockholders waiting patiently for a return. GlaxoSmithKline and Xenoport announced today that the FDA has approved its Horizant new drug for postherpetic neuralgia (PHN) in adults...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *